Clinical Trial Update: Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating niraparib in combination with aromatase inhibitors for luminal-like, HER2-negative, ER-positive metastatic breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitors (aromatase inhibitor)
• Niraparib (Niraparib)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer, Breast Cancer Metastatic | Phase 2 | Status: COMPLETED